The dramatic rise of spending on and utilization of GLP-1 receptor agonists (CLP-1 RA) for therapeutical purposes is a growing UM focus area. In a value-based context, the objective remains not to restrict access to such therapies, but to ensure that deployment strategies balance access, evidence-based indications, and long-term sustainability.
AAVBC’s Quick Reference Guide incorporates current clinical evidence as well as CMS-aligned decision-making guidelines for the proper deployment of incretin therapies. This guide provides clinicians and health providers with actionable criteria and documentation strategies to optimize this aspect of the healthcare ecosystem for cost savings without sacrificing safety and long-term care quality.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of GLP-1 RA utilization — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, sustainability, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of the GLP-1 RA landscape and utilization, and provide care teams with the necessary strategies to thrive within a value-based framework.
The dramatic rise of spending on and utilization of GLP-1 receptor agonists (CLP-1 RA) for therapeutical purposes is a growing UM focus area. In a value-based context, the objective remains not to restrict access to such therapies, but to ensure that deployment strategies balance access, evidence-based indications, and long-term sustainability.
AAVBC’s Quick Reference Guide incorporates current clinical evidence as well as CMS-aligned decision-making guidelines for the proper deployment of incretin therapies. This guide provides clinicians and health providers with actionable criteria and documentation strategies to optimize this aspect of the healthcare ecosystem for cost savings without sacrificing safety and long-term care quality.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of GLP-1 RA utilization — moving far beyond quick-reference essentials. These guides provide an integrated review of financial implications, decision frameworks, target conditions, risk stratifications, sustainability, document requirements as well as billing and coding considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of the GLP-1 RA landscape and utilization, and provide care teams with the necessary strategies to thrive within a value-based framework.
